To address the paucity of effective treatments for disorders of the nervous system, the NIH has established the Blueprint Neurotherapeutics Network (http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm). This program intends to develop drugs successfully through clinical Phase I and facilitate industry partnerships for their full development. The long-term goal of this grand challenge is to produce at least one novel and effective medication for a disorder of the nervous system that is currently poorly treated or untreated. The NIH Blueprint Neurotherapeutics Network is establishing a ?virtual pharma? network of contract service providers and consultants with extensive industry experience to enable drug development in the NIH neuroscience research community. The Network offers neuroscience researchers access to a full range of industry-style drug development services and expertise, including medicinal chemistry, IND-enabling studies, and Phase 1 clinical trial infrastructure. The Pharmacology and Toxicology for Neurotherapeutics Program (PTNP) contracts support all preclinical pharmacology and toxicology testing needed to inform lead optimization and the selection of a clinical candidate, and comprehensive studies needed for an Investigational New Drug (IND) application for the FDA to allow for clinical evaluation of New Chemical Entities.

Agency
National Institute of Health (NIH)
Type
Research and Development Contracts (N01)
Project #
271201100004I-0-27100008-2
Application #
8739910
Study Section
Project Start
2013-04-10
Project End
2014-04-09
Budget Start
Budget End
Support Year
Fiscal Year
2013
Total Cost
$1,511,951
Indirect Cost
Name
Sri International
Department
Type
DUNS #
009232752
City
Menlo Park
State
CA
Country
United States
Zip Code
94025